1.646.889.1200|info@lifescipublicrelations.com

For tiny biotechs, J.P. Morgan is a big opportunity — and a big cost

//For tiny biotechs, J.P. Morgan is a big opportunity — and a big cost

For tiny biotechs, J.P. Morgan is a big opportunity — and a big cost

The company, which is working on drugs based on antisense oligonucleotides to treat genetic conditions, announced a reverse merger with Ohr Pharmaceutical on Jan. 3, which would allow its stock to trade publicly.

By | 2019-01-17T16:49:52-04:00 January 10th, 2019|News|Comments Off on For tiny biotechs, J.P. Morgan is a big opportunity — and a big cost

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.